Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Inflammatory Bowel Diseases

  Free Subscription


22.05.2017

1 Aliment Pharmacol Ther
1 Clin Res Hepatol Gastroenterol
1 Dig Dis Sci
1 Drugs
1 Gastroenterology
12 Inflamm Bowel Dis
1 J Clin Gastroenterol
4 J Crohns Colitis
1 Mediators Inflamm
3 Scand J Gastroenterol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. DAMAS OM, Avalos DJ, Palacio AM, Gomez L, et al
    Inflammatory bowel disease is presenting sooner after immigration in more recent US immigrants from Cuba.
    Aliment Pharmacol Ther. 2017 May 19. doi: 10.1111/apt.14145.
    PubMed     Text format     Abstract available


    Clin Res Hepatol Gastroenterol

  2. DAI SX, Gu HX, Lin QY, Huang SZ, et al
    CD8+CD28+/CD8+CD28- T cell equilibrium can predict the active stage for patients with inflammatory bowel disease.
    Clin Res Hepatol Gastroenterol. 2017 May 10. pii: S2210-7401(17)30088.
    PubMed     Text format     Abstract available


    Dig Dis Sci

  3. LAZARIDIS LD, Pistiki A, Giamarellos-Bourboulis EJ, Georgitsi M, et al
    Activation of NLRP3 Inflammasome in Inflammatory Bowel Disease: Differences Between Crohn's Disease and Ulcerative Colitis.
    Dig Dis Sci. 2017 May 18. doi: 10.1007/s10620-017-4609.
    PubMed     Text format     Abstract available


    Drugs

  4. FLAMANT M, Rigaill J, Paul S, Roblin X, et al
    Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects.
    Drugs. 2017 May 18. doi: 10.1007/s40265-017-0755.
    PubMed     Text format     Abstract available


    Gastroenterology

  5. YADAV P, Ellinghaus D, Remy G, Freitag-Wolf S, et al
    Genetic Factors Interact With Tobacco Smoke to Modify Risk for Inflammatory Bowel Disease in Humans and Mice.
    Gastroenterology. 2017 May 12. pii: S0016-5085(17)35596.
    PubMed     Text format     Abstract available


    Inflamm Bowel Dis

  6. NGUYEN GC, Boland K, Afif W, Bressler B, et al
    Modified Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2017 May 15. doi: 10.1097/MIB.0000000000001152.
    PubMed     Text format     Abstract available

  7. YADAV A, Foromera J, Feuerstein I, Falchuk KR, et al
    Variations in Health Insurance Policies Regarding Biologic Therapy Use in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2017 May 15. doi: 10.1097/MIB.0000000000001153.
    PubMed     Text format     Abstract available

  8. BERRY AC, Dholaria K, Czul-Gurdian F, Forster E, et al
    Relationship Between Patient Knowledge and Medication Adherence in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2017;23:E39-E40.
    PubMed     Text format    

  9. HOPKINS CWP, Butt HS, Moulton CD
    Beyond Efficacy: The Acceptability of Antidepressant Treatment to Patients with Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2017;23:E38.
    PubMed     Text format    

  10. YADAV A, Foromera J, Feuerstein I, Falchuk KR, et al
    Variations in Health Insurance Policies Regarding Biologic Therapy Use in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2017;23:853-857.
    PubMed     Text format     Abstract available

  11. NGUYEN GC, Boland K, Afif W, Bressler B, et al
    Modified Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2017;23:858-865.
    PubMed     Text format     Abstract available

  12. HEIDA A, Park KT, van Rheenen PF
    Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide.
    Inflamm Bowel Dis. 2017;23:894-902.
    PubMed     Text format     Abstract available

  13. BORREN NZ, Conway G, Tan W, Andrews E, et al
    Distance to Specialist Care and Disease Outcomes in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2017 May 16. doi: 10.1097/MIB.0000000000001133.
    PubMed     Text format     Abstract available

  14. VALER P, Algaba A, Santos D, Fuentes ME, et al
    Evaluation of the Quality of Semen and Sexual Function in Men with Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2017 May 16. doi: 10.1097/MIB.0000000000001081.
    PubMed     Text format     Abstract available

  15. FATTAHI MR, Malek-Hosseini SA, Sivandzadeh GR, Safarpour AR, et al
    Clinical Course of Ulcerative Colitis After Liver Transplantation in Patients with Concomitant Primary Sclerosing Cholangitis and Ulcerative Colitis.
    Inflamm Bowel Dis. 2017 May 16. doi: 10.1097/MIB.0000000000001105.
    PubMed     Text format     Abstract available

  16. AXELRAD JE, Joelson A, Nobel YR, Lawlor G, et al
    Enteric Infection in Relapse of Inflammatory Bowel Disease: The Utility of Stool Microbial PCR Testing.
    Inflamm Bowel Dis. 2017;23:1034-1039.
    PubMed     Text format     Abstract available

  17. GLASSNER K, Malaty HM, Abraham BP
    Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease Among Patients with Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2017;23:998-1003.
    PubMed     Text format     Abstract available


    J Clin Gastroenterol

  18. FERREIRO-IGLESIAS R, Barreiro-de Acosta M, Dominguez-Munoz JE
    Reply to: Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease Patients.
    J Clin Gastroenterol. 2017 May 17. doi: 10.1097/MCG.0000000000000839.
    PubMed     Text format    


    J Crohns Colitis

  19. HARBORD M, Eliakim R, Bettenworth D, Karmiris K, et al
    Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management.
    J Crohns Colitis. 2017 Jan 28. doi: 10.1093.
    PubMed     Text format    

  20. COX SR, Prince AC, Myers CE, Irving PM, et al
    Fermentable carbohydrates (FODMAPs) exacerbate functional gastrointestinal symptoms in patients with inflammatory bowel disease: a randomised, double-blind, placebo-controlled, cross-over, re-challenge trial.
    J Crohns Colitis. 2017 May 19. doi: 10.1093.
    PubMed     Text format     Abstract available

  21. CARBONNEL F, Boutron MC
    Incidence, phenotype and mortality of inflammatory bowel disease twenty years after.
    J Crohns Colitis. 2017 May 19. doi: 10.1093.
    PubMed     Text format    

  22. KAROLEWSKA-BOCHENEK K, Dziekiewicz M, Banaszkiewicz A
    Budesonide MMX in pediatric patients with ulcerative colitis.
    J Crohns Colitis. 2017 May 15. doi: 10.1093.
    PubMed     Text format    


    Mediators Inflamm

  23. DUVOISIN G, Lopez RN, Day AS, Lemberg DA, et al
    Novel Biomarkers and the Future Potential of Biomarkers in Inflammatory Bowel Disease.
    Mediators Inflamm. 2017;2017:1936315.
    PubMed     Text format     Abstract available


    Scand J Gastroenterol

  24. SEO H, Chang K, Lee SH, Song EM, et al
    Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea.
    Scand J Gastroenterol. 2017 May 14:1-7. doi: 10.1080/00365521.2017.1323229.
    PubMed     Text format     Abstract available

  25. KOKKINIDIS DG, Bosdelekidou EE, Iliopoulou SM, Tassos AG, et al
    Emerging treatments for ulcerative colitis: a systematic review.
    Scand J Gastroenterol. 2017 May 14:1-9. doi: 10.1080/00365521.2017.1326163.
    PubMed     Text format     Abstract available

  26. JACKSON B, Con D, Ma R, Gorelik A, et al
    Health care costs associated with Australian tertiary inflammatory bowel disease care.
    Scand J Gastroenterol. 2017 May 16:1-6. doi: 10.1080/00365521.2017.1323117.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: